Value Investor
Start free

OnKure Therapeutics

OKUR on Nasdaq. Market value $107m.

Watch this stockFree. We tell you when something changes.

Should I look at this?

Not a fit for our list right now

Why it could be worth it

Nothing stands out yet.

What to watch out for

See Health care stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
-37.9%low

For every $100 of what the whole company costs, it produced $-37.90 of spare cash last year. A savings account pays about $4.

Price to profit
n/a

The filings do not give us enough to work this out.

Return on capital
n/a

The filings do not give us enough to work this out.

Quality score: not known. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.

Five years of cash, in billions

-0.1
2024
Revenue
$0
Operating margin
n/a
Debt to equity
n/a
Shares outstanding
0.03bn

Health checks

  • Free cash flow positive0 of 5 years
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)1 of 9
  • Profit backed by cash (accruals)Yes
  • DebtUnknown
  • Revenue growth, five yearsUnknown
  • Buying back its own sharesRoughly flat

Dates

Next results (estimated)
n/a
Last annual report (10-K)
12 March 2026
Next quarterly (estimated, 10-Q)
3 November 2026

Who owns it

None of the long-term investors we follow own it. 75 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

14 investors own more than 5%.

  • AI Biotechnology LLC
    Passive investor
    at least 20.0%
    (filed with 3 related holders)
    Since 31 March 2026
    What they said

    The information set forth in Item 3 and Item 6 hereof is hereby incorporated herein by reference. The Reporting Persons who hold securities of the Issuer directly acquired those securities as an investment in the regular course of their businesses. The Reporting Persons may…

    Read the filing
  • ACORN CAPITAL ADVISORS GP, LLC
    Passive investor
    at least 13.3%0.0 pts
    (filed with 1 related holder)
    Since 15 May 2025
    What they said

    The shares of Common Stock reported herein were acquired solely for investment purposes. None of the Reporting Persons have any present plans or proposals that relate to or would result in any change in the business, policies, management, structure or capitalization of the…

    Read the filing
  • at least 9.9%
    (filed with 3 related holders)
    Since 31 March 2026
  • Anders Hove
    Passive investor
    at least 9.5%−12.6 pts
    (filed with 4 related holders)
    Since 27 March 2026
  • BVF PARTNERS L P/IL
    Passive investor
    at least 8.0%+2.7 pts
    (filed with 9 related holders)
    Since 30 June 2026
  • StepStone Group LP
    Passive investor
    at least 6.6%
    (filed with 2 related holders)
    Since 31 March 2026
  • Shay Capital LLC
    Passive investor
    at least 6.3%
    (filed with 1 related holder)
    Since 15 May 2025
  • at least 5.5%−0.5 pts
    (filed with 2 related holders)
    Since 30 June 2026
  • Cantor Fitzgerald Securities
    Passive investor
    at least 5.2%
    (filed with 2 related holders)
    Since 30 June 2025
  • Deep Track Capital, LP
    Passive investor
    at least 4.1%
    (filed with 2 related holders)
    Since 31 December 2024
  • at least 3.6%−2.4 pts
    (filed with 2 related holders)
    Since 30 June 2026
  • Prosight Management, LP
    Passive investor
    at least 2.4%−3.4 pts
    (filed with 4 related holders)
    Since 30 June 2026
  • Kenneth Griffin
    Passive investor
    at least 1.7%
    (filed with 6 related holders)
    Since 31 December 2025
  • John P. McKearn, Ph.D.
    Passive investor
    at least 1.6%
    (filed with 10 related holders)
    Since 16 January 2025
  • The Vanguard Group
    Passive investor
    Sold down below 5%
    Since 31 December 2025
  • Sold down below 5%
    Since 31 December 2025
  • Lundbeckfond Invest A/S
    Passive investor
    Sold down below 5%
    Since 31 December 2024
  • Joseph Edelman
    Passive investor
    Sold down below 5%
    Since 30 June 2025
  • Samsara BioCapital, L.P.
    Passive investor
    Sold down below 5%
    Since 30 June 2025
  • Sold down below 5%
    Since 15 May 2025

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought shares on the open market in the last 12 months. 2 sold $5,634.

  • Leverone Jason A.
    Chief Financial Officer
    Sold
    Date
    21 September 2026
    Shares
    302
    Price
    $2.97
    Value
    $898
  • Saccomano Nicholas A
    President and CEO, Director
    Sold
    Date
    21 September 2026
    Shares
    87
    Price
    $2.97
    Value
    $259
  • Leverone Jason A.
    Chief Financial Officer
    Sold
    Date
    22 June 2026
    Shares
    303
    Price
    $4.40
    Value
    $1,333
  • Saccomano Nicholas A
    President and CEO, Director
    Sold
    Date
    22 June 2026
    Shares
    86
    Price
    $4.40
    Value
    $378
  • Leverone Jason A.
    Chief Financial Officer
    Sold
    Date
    23 March 2026
    Shares
    301
    Price
    $4.16
    Value
    $1,252
  • Saccomano Nicholas A
    President and CEO, Director
    Sold
    Date
    23 March 2026
    Shares
    86
    Price
    $4.16
    Value
    $358
  • Leverone Jason A.
    Chief Financial Officer
    Sold
    Date
    22 December 2025
    Shares
    302
    Price
    $2.97
    Value
    $897
  • Saccomano Nicholas A
    President and CEO, Director
    Sold
    Date
    22 December 2025
    Shares
    87
    Price
    $2.97
    Value
    $258

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the serious warning signs we check for were found. 1 thing worth knowing.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 12 Mar 2026, plus the 10-Q filed 4 Aug 2026 and 5 later 8-Ks.

  • Changed auditor

    Worth knowing

    The company changed its auditor (the firm that checks its books) in the last two years.

    “On November 7, 2024, Ernst & Young LLP ("EY") was dismissed as the independent registered public accounting firm of OnKure Therapeutics, Inc. (formerly Reneo Pharmaceuticals, Inc.) (the "Company").”

    From an 8-K filed 7 November 2024: Change of auditor. Read it in the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.